REGENXBIO Inc.
RGNX
$9.66
$0.293.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.00% | -43.96% | 104.54% | 91.30% | 74.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.00% | -43.96% | 104.54% | 91.30% | 74.95% |
| Cost of Revenue | 3.33% | 8.77% | 2.69% | -3.83% | -3.29% |
| Gross Profit | 11.85% | -108.62% | 50.77% | 52.46% | 45.76% |
| SG&A Expenses | 14.53% | 13.77% | 15.70% | 0.78% | -4.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -82.04% | -78.12% | -79.31% | 538.67% | 179.28% |
| Total Operating Expenses | 5.70% | 9.69% | 5.43% | -2.52% | -3.50% |
| Operating Income | 0.27% | -63.13% | 30.29% | 35.47% | 32.25% |
| Income Before Tax | -11.88% | -83.91% | 14.63% | 25.55% | 27.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.88% | -83.91% | 14.63% | 25.50% | 27.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.88% | -83.91% | 14.63% | 25.50% | 27.17% |
| EBIT | 0.27% | -63.13% | 30.29% | 35.47% | 32.25% |
| EBITDA | -0.02% | -70.60% | 32.30% | 37.75% | 34.19% |
| EPS Basic | -10.06% | -79.85% | 18.59% | 31.22% | 34.76% |
| Normalized Basic EPS | -10.06% | -79.85% | 17.77% | 29.44% | 33.15% |
| EPS Diluted | -10.02% | -80.03% | 18.52% | 31.15% | 34.72% |
| Normalized Diluted EPS | -10.10% | -79.84% | 17.77% | 29.44% | 33.15% |
| Average Basic Shares Outstanding | 2.04% | 1.83% | 4.18% | 7.47% | 10.98% |
| Average Diluted Shares Outstanding | 2.10% | 1.79% | 4.22% | 7.50% | 11.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |